Early intervention with daratumumab improves survival for patients with high-risk smouldering myeloma

Recent results from the phase III AQUILA trial demonstrate the benefit of fixed-duration monotherapy with daratumumab over observation in patients with high-risk smouldering multiple

myeloma, which changes the early interception treatment landscape. Herein, we discuss how future studies could build on this success and pave the way to eradicating multiple myeloma before

it starts. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Access

Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print

issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to

local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES *

Ghobrial, I. M. et al. Round table discussion on optimal clinical trial design in precursor multiple myeloma. _Blood Cancer Discov._ 5, 146–152 (2024). Article  PubMed  PubMed Central 

Google Scholar  * Mateos, M. V. et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). _Blood Cancer J._ 10, 102 (2020). Article  PubMed

  PubMed Central  Google Scholar  * Lakshman, A. et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. _Blood Cancer J._ 8, 59 (2018).

Article  PubMed  PubMed Central  Google Scholar  * Cowan, A. et al. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering

multiple myeloma (PANGEA): a retrospective, multicohort study. _Lancet Haematol._ 10, e203–e212 (2023). Article  CAS  PubMed  PubMed Central  Google Scholar  * Dutta, A. K. et al.

MinimuMM-seq: genome sequencing of circulating tumor cells for minimally invasive molecular characterization of multiple myeloma pathology. _Cancer Discov._ 13, 348–363 (2023). Article  CAS

  PubMed  Google Scholar  * Mateos, M. V. et al. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: a randomized,

open-label study. _Eur. J. Cancer_ 174, 243–250 (2022). Article  CAS  PubMed  Google Scholar  * Lonial, S. et al. Randomized trial of lenalidomide versus observation in smoldering multiple

myeloma. _J. Clin. Oncol._ 38, 1126–1137 (2020). Article  CAS  PubMed  Google Scholar  * Dimopoulos, M. A. et al. Daratumumab or active monitoring for high-risk smoldering multiple myeloma.

_N. Engl. J. Med._ https://doi.org/10.1056/NEJMoa2409029 (2024). Article  PubMed  Google Scholar  * Nadeem, O. et al. Immuno-PRISM: a randomized phase II platform study of bispecific

antibodies in high-risk smoldering myeloma. _Blood_ 142 (Suppl. 1), 206 (2023). Article  Google Scholar  * Nadeem, O. et al. Early safety and efficacy of CAR-T cell therapy in precursor

myeloma: results of the CAR-PRISM study using ciltacabtagene autoleucel in high-risk smoldering myeloma. _Blood_ 144 (Suppl. 1), 1027 (2024). Article  Google Scholar  Download references

AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Omar

Nadeem & Irene M. Ghobrial Authors * Omar Nadeem View author publications You can also search for this author inPubMed Google Scholar * Irene M. Ghobrial View author publications You

can also search for this author inPubMed Google Scholar CORRESPONDING AUTHORS Correspondence to Omar Nadeem or Irene M. Ghobrial. ETHICS DECLARATIONS COMPETING INTERESTS O.N. has received

research support from Janssen and Takeda; has been an advisory board member for Bristol Myers Squibb, GPCR therapeutics, Janssen, Sanofi and Takeda; and has received honoraria from Pfizer.

I.M.G. has been a paid consultant for 10X Genomics, AbbVie, Adaptive Biotechnologies, Amgen, Aptitude Health, Binding Site (part of Thermo Fisher Scientific), Bristol Myers Squibb,

GlaxoSmithKline, Janssen, Menarini Silicon Biosystems, Novartis, Pfizer, Regeneron, Sanofi, Standard Biotools, and Takeda. She is a founder and board member of, and holds private equity in,

Predicta Biosciences; and her spouse is the chief medical officer of, and holds private equity in, Disc Medicine. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS

ARTICLE Nadeem, O., Ghobrial, I.M. Early intervention with daratumumab improves survival for patients with high-risk smouldering myeloma. _Nat Rev Clin Oncol_ 22, 159–160 (2025).

https://doi.org/10.1038/s41571-025-00987-2 Download citation * Published: 24 January 2025 * Issue Date: March 2025 * DOI: https://doi.org/10.1038/s41571-025-00987-2 SHARE THIS ARTICLE Anyone

you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by

the Springer Nature SharedIt content-sharing initiative